Full View

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long‐term side effects

C Krittanawong, T Kitai - Cardiovascular therapeutics, 2017 - Wiley Online Library
The development of the promising agent sacubitril/valsartan, known as an angiotensin
receptor blocker‐neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may …
被引用次数：31 相关文章

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects

C Krittanawong, T Kitai - Cardiovascular therapeutics, 2017 - pubmed.ncbi.nlm.nih.gov
The development of the promising agent sacubitril/valsartan, known as an angiotensin
receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may …

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.

C Krittanawong, T Kitai - Cardiovascular Therapeutics, 2017 - europepmc.org
The development of the promising agent sacubitril/valsartan, known as an angiotensin
receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may …

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.

C Krittanawong, T Kitai - Cardiovascular Therapeutics, 2017 - search.ebscohost.com
The development of the promising agent sacubitril/valsartan, known as an angiotensin
receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may …